| Name | Title | Contact Details |
|---|---|---|
Adam Carreno |
Chief Executive Officer and Technology Advisor | Profile |
Yokogawa Electric Corporation is a global leader in measurement, control, and information technologies. Founded in 1915 in Tokyo, Japan, the company began as a small laboratory focused on producing instruments that were primarily imported at the time. Today, Yokogawa operates in 60 countries and employs over 17,365 people, with a significant presence in North America. The company offers a diverse range of products and services, including measurement instruments, advanced control solutions for industrial automation, and information technologies for data management and analysis. Yokogawa serves various industries such as energy, chemicals, pharmaceuticals, and food, helping clients tackle complex production and operations management challenges. Their commitment to quality, innovation, and societal contribution guides their operations and partnerships with customers.
In 2015, an important group of investors alongside a group of experienced professionals in the Reinsurance industry, acquired a majority interest in MBI Americas. Now, XS Global, a well-known regional MGA and Coverholder at Lloyds. The groups footprint and ambitions now encompass the underwriting space, utilizing strong synergies that exist between the groups core business strategy. Our unique structure provides us opportunities to deploy targeted reinsurance capacity both directly to corporates and to retail brokers via expert and locally based underwriters. We are proud to say we invest in talent and our team has proven skills, excellent access, and a proven track record for underwriting profitable business in the Latin America region and beyond.
We are a trailblazing brand dedicated to inspiring and empowering women in sports. Our high-performance gear and cutting-edge technology enhance abilities and boost confidence. We create a supportive community that celebrates achievements, fosters connections, and encourages collaboration. Authentic, persevering, and dedicated to excellence, we redefine what it means to be a force in womens sports
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Citizens Bank & Trust Company of Campbellsville, KY is a banking company based out of 201 E MAIN ST, Campbellsville, Kentucky, United States.